Abstract
BackgroundPulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. Thus, the clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored.ResultsThe clinical data of 59 patients (48 males and 11 females) who were treated by surgery and diagnosed with pLCNEC by postoperative pathology at Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively. The median patient age was 62 years (38–79 years), and the median duration of disease was 2 months (0.5–18 months). Compared with other lung malignancies, pLCNEC lacks specific clinical symptoms and imaging features, and preoperative biopsy pathology is often insufficient to confirm the diagnosis. The corresponding numbers of patients who were classified into stages I, II, III and IV according to the postoperative pathological tumour-nodal-metastasis stage were 25, 12, 15 and 7, respectively. The median overall survival was 36 months (0.9–61.1 months). The 1-year, 3-year and 5-year survival rates were 76.3%, 49% and 44.7%, respectively. The tumour stage exerted a significant effect on survival (Cox multivariate analysis p < 0.05).ConclusionsFor patients with resectable pLCNEC, multidisciplinary therapy based on surgery may have good survival benefits, and tumour stage is an independent risk factor for the prognosis of pLCNEC.
Highlights
Pulmonary large-cell neuroendocrine carcinoma is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood
Pulmonary large-cell neuroendocrine carcinoma is a very rare malignant tumour originating from the lung and bronchus
Combining our data with the findings of other previously reported cohort studies on the surgical treatment of Pulmonary large-cell neuroendocrine carcinoma (pLCNEC), we summarized the curative effect of comprehensive treatment based on surgery and analysed the potential prognostic factors
Summary
Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. The clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored. Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignant tumour originating from the lung and bronchus. It was first reported in 1989 and summarized by Travis et al [1]. Combining our data with the findings of other previously reported cohort studies on the surgical treatment of pLCNEC, we summarized the curative effect of comprehensive treatment based on surgery and analysed the potential prognostic factors
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
